Integrating Genetic Variants and Expression Profiles of Pharmacogenes to Investigate Resistance to Antidepressant Treatment.

Analyses on specific metabolizer phenotypes showed a trend for higher frequency of CYP2D6 ultrarapid metabolizers (UMs) in remitters compared with non-remitters in patients with TRD (χ 2 = 4.76, p = 0.045), but not in patients without TRD (χ 2 = 0.02, p = 1.00, Supplementary Table S9 ).

also in 25,348 other papers

CYP2C19 phenotypes showed a nominally significant association with TRD (χ 2 = 9.64, p = 0.047, Table 2 and Supplementary Table S6 ) in the whole sample, but not when limiting the analysis to patients treated with antidepressants with clinical annotations for CYP2C19 reported in ClinPGX ( Supplementary Table S7 ).

also in 3,395 other papers